BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: This new structural variant complex shows anti-tumor activity on chronic myeloid leukemia by targeting the IL-8, survivin, and induces apoptosis through DNA fragmentation, but not against normal cells.